Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04915950 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04915950 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 13 participants.
The verdict
NCT04915950, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for symptoms associated with SSc-RP.
Interventions
- DRUG Placebo
- DRUG Temanogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2022-09-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04915950
The ClinicalTrials.gov registry entry for NCT04915950 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04915950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04915950 about?
NCT04915950 is a clinical study titled "A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis". The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for symptoms associated with SSc-RP.
What is the current status of trial NCT04915950?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2021-11-03. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT04915950?
The interventions under investigation include: Placebo (DRUG), Temanogrel (DRUG).
Who is sponsoring clinical trial NCT04915950?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.